Bioventix Plc

Director/PDMR Shareholding

Bioventix plc

(“Bioventix” or the “Company”)

Director/PDMR Shareholding

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 19 October 2017 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”):

Director Position Ordinary Shares sold Sale price per Ordinary Share Ordinary Shares held subsequently Percentage of issued share capital held subsequently
Ian Nicholson and Persons Closely Associated Non-Executive Chairman 5,000 2400.75p 18,000 0.4%
Peter Harrison and Persons Closely Associated CEO 80,000 2425.00p 428,176 8.3%

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Details of the person discharging managerial responsibilities / person closely associated
a) Names Ian Nicholson (Non-Executive Chairman)
Catherine Nicholson (PCA with Ian Nicholson)
Peter Harrison (CEO)
Reason for the Notification
a) Position/status See 1(a) above, all are PDMR’s or PCA’s of PDMR’s
b) Initial notification/Amendment Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name Bioventix plc
b) LEI 213800225MHX7LZQY108
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the Financial instrument, type of instrument Ordinary shares of 5 pence (“Ordinary Shares”)
Identification code GB00B4QVDF07
b) Nature of the transaction In each case, sale of Ordinary Shares
c) Price(s) and volume(s)

Ian Nicholson:

Price(s) Volume(s)
2400.75p 2,500

Catherine Nicholson:

Price(s) Volume(s)
2400.75p 2,500

Peter Harrison:

Price(s) Volume(s)
2425.00p 80,000
d) Aggregated information: See 4(c)
e) Date of the transaction 19 October 2017
f) Place of the transaction London Stock Exchange, AIM Market (XLON)

For further information please contact:

Bioventix plc
Peter Harrison

Chief Executive Officer
Tel: 01252 728 001
finnCap Ltd
Geoff Nash/Simon Hicks
Stephen Norcross

Corporate Finance
Corporate Broking
Tel: 020 7220 0500

About Bioventix plc:

Bioventix ( specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.